Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04606316 · ClinicalTrials.gov registry record · Phase 1
Surgical Nivolumab And Ipilimumab For Recurrent GBM
A Phase 1 study of Glioblastoma and Glioblastoma Multiforme, sponsored by Patrick Wen, MD.
- Active
- Registry status
- Phase 1
- Development phase
- 63
- Enrollment target
- 4
- Study locations
NCT04606316: Active Phase 1 study of Glioblastoma and Glioblastoma Multiforme, sponsored by Patrick Wen, MD.
NCT04606316 is a Phase 1 study of Glioblastoma and Glioblastoma Multiforme that is active but no longer recruiting, run by Patrick Wen, MD. The registered enrollment target is 63 participants, below the 109-participant average among 199 other Glioblastoma trials with a reported enrollment target (42% lower). The trial reports 4 study locations across 3 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04606316, a Phase 1 study of Glioblastoma and Glioblastoma Multiforme, is active but no longer recruiting, sponsored by Patrick Wen, MD.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 1
- Development phase
- 63 participants
- Enrollment target
- 4
- Study locations
Study Summary
This research trial is studying the safety and effectiveness of nivolumab in combination with ipilimumab and surgery when used in the treatment of recurrent glioblastoma. The names of the study drugs involved in this study are: * Nivolumab * Ipilimumab * Placebo (IV solution with no medicine) * Zr-89 Crefmirlimab berdoxam (optional sub-study)
Primary Outcome
TIL density will be assessed and compared between the three arms using the Two-sample t-Test.
Conditions Studied
Interventions
- DRUG Nivolumab
- DRUG Ipilimumab
- PROCEDURE Surgery
- DRUG Nivolumab-Placebo
- DRUG Ipilimumab-Placebo
Study Locations (4)
California
- University of California Los Angeles - Los Angeles
- Stanford University - Stanford
Massachusetts
- Dana Farber Cancer Institute - Boston
New York
- Memorial Sloan Kettering Cancer Center - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 63 participants |
| Start Date | 2021-02-01 |
| Est. Completion | 2026-12-31 |
| Phase | Phase 1 |
What the registry record for NCT04606316 still lists
NCT04606316 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 63 participants, a relatively small participant target, below the 109-participant average among 199 other Glioblastoma trials with a reported enrollment target (42% lower).
The record links to 4 conditions, with Glioblastoma appearing as the primary indexed condition, and to 5 interventions - of which Nivolumab is the first listed.
NCT04606316 reports a single indexed study location in California, Massachusetts, New York.
Frequently Asked Questions
What is clinical trial NCT04606316 about?
NCT04606316 is a clinical study titled "Surgical Nivolumab And Ipilimumab For Recurrent GBM". This research trial is studying the safety and effectiveness of nivolumab in combination with ipilimumab and surgery when used in the treatment of recurrent glioblastoma. The names of the study drugs involved in this study are: * Nivolumab * Ipilimumab * Placebo (IV solution with no medicine) * Zr...
What is the current status of trial NCT04606316?
This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 63 participants. The study started on 2021-02-01. Estimated completion is 2026-12-31.
What conditions does trial NCT04606316 study?
This clinical trial studies the following conditions: Glioblastoma, Glioblastoma Multiforme, GBM, Grade IV Astrocytoma.
What interventions are being tested in trial NCT04606316?
The interventions under investigation include: Nivolumab (DRUG), Ipilimumab (DRUG), Surgery (PROCEDURE), Nivolumab-Placebo (DRUG), Ipilimumab-Placebo (DRUG).
Who is sponsoring clinical trial NCT04606316?
This trial is sponsored by Patrick Wen, MD, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04606316 being conducted?
This trial has 4 study locations across California, Massachusetts, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Glioblastoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04606316's enrollment target sits among peer trials
63 70th of 199 higher than 130 of 199 other Glioblastoma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Glioblastoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Super-selective Intra-arterial Repeated Infusion of Cetuximab for the Treatment of Newly Diagnosed Glioblastoma
RECRUITING · Phase 1
-
A Phase I/II Study of IVONESCIMAB in Recurrent Glioblastoma
RECRUITING · Phase 1
-
CARv3-TEAM-E T Cells in Glioblastoma
RECRUITING · Phase 1
-
CUE-102 in Recurrent Glioblastoma
RECRUITING · Phase 1
-
Adenovirus Mediated Suicide Gene Therapy With Radiotherapy in Progressive Astrocytoma.
RECRUITING · Phase 1
-
Laser Interstitial Thermal Therapy (LITT) and Lomustine (CCNU) for Recurrent Glioblastoma
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03383575 · 63 participants · Phase 2
Azacitidine and Enasidenib in Treating Patients With IDH2-Mutant Myelodysplastic Syndrome
- NCT04870944 · 63 participants · Phase 1
CBL0137 for the Treatment of Relapsed or Refractory Solid Tumors, Including CNS Tumors and Lymphoma
- NCT05031897 · 63 participants · Phase 2
Two Step Haplo With Radiation Conditioning
- NCT05312671 · 63 participants · Phase 2
Atezolizumab Plus Etoposide and Platinum in Small Cell Bladder Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI